Nevertheless, these results suggest that the primary tumor location may not be the sole determinant and support the notion that primary tumor location serves as a clinical surrogate marker reflecting the intricate molecular landscape of primary resistance to anti-EGFR antibodies. This evidence concerns the gene EGFR and neoplasm.